Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23N7O5.4H2O |
Molecular Weight | 477.4695 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(N)=O
InChI
InChIKey=HRCJDWMUKPHPHR-NTFWNTCYSA-N
InChI=1S/C17H23N7O5.4H2O/c1-23-13(25)6-10(22-17(23)29)15(27)21-11(5-9-7-19-8-20-9)16(28)24-4-2-3-12(24)14(18)26;;;;/h7-8,10-12H,2-6H2,1H3,(H2,18,26)(H,19,20)(H,21,27)(H,22,29);4*1H2/t10-,11-,12-;;;;/m0..../s1
Molecular Formula | C17H23N7O5 |
Molecular Weight | 405.4084 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15931571Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/taltirelin.html | https://www.ncbi.nlm.nih.gov/pubmed/23087672 | https://www.ncbi.nlm.nih.gov/pubmed/25142535
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15931571
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/taltirelin.html | https://www.ncbi.nlm.nih.gov/pubmed/23087672 | https://www.ncbi.nlm.nih.gov/pubmed/25142535
Taltirelin (TA-0910), a synthetic thyrotropin-releasing hormone (TRH) analog, has been developed by Tanabe Seiyaku for the treatment of neurodegenerative diseases. Taltirelin mimics the physiological actions of TRH, but with a much longer half-life and duration of effects, and little development of tolerance following prolonged dosing. Taltirelin has nootropic, neuroprotective and analgesic effects. Taltirelin is primarily being researched for the treatment of spinocerebellar ataxia; limited research has also been carried out with regard to other neurodegenerative disorders, e.g., spinal muscular atrophy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1810 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23087672 |
36.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ceredist Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Taltirelin (Tanabe Seiyaku). | 2001 Dec |
|
Brain receptor binding characteristics and pharmacokinetic-pharmacodynamic analysis of thyrotropin-releasing hormone analogues. | 2001 Dec 28 |
|
Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice. | 2013 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15931571
Patients took taltirelin (5 mg bid) or placebo for 28 to 52 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23087672
HEK-EM 293 (human embryonic kidney) cells stably expressing TRH-R were seeded in black-walled, clear bottomed 96-well plates (Corning, NY, USA) at a density of 60,000 cells/well in DMEM with 10% fetal bovine serum and incubatedfor24hat37◦C in5%CO2. The following day, the culture media was replaced with 100 μl of Hank’s balanced salt solution with 20 mM HEPES, pH 7.5 and the cells were loaded with100 μl of calcium 4 fluorescent dye (Molecular Devices, Sunnyvale, CA, USA) for 1 h at room temperature before addition of compounds .Transient changes in intracellular [Ca++] induced by TALTIRELIN were measured using the FLIPRTETRA system (Molecular Devices, Sunnyvale, CA, USA). Changes in fluorescence were detected at the emission wavelength ranges from 515 to 575 nm. The agonistic responses of ligands were assessed immediately upon their addition in a concentration range from 0.1 nMto30 μM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:01:26 GMT 2023
by
admin
on
Sat Dec 16 07:01:26 GMT 2023
|
Record UNII |
525OEO6W15
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C76367
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000013131
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | |||
|
157598
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | |||
|
656609
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | |||
|
525OEO6W15
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | |||
|
C79830
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | NCIT | ||
|
m10447
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID3021300
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY | |||
|
201677-75-0
Created by
admin on Sat Dec 16 07:01:26 GMT 2023 , Edited by admin on Sat Dec 16 07:01:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |